-
Je něco špatně v tomto záznamu ?
ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective
T. Koessler, M. Alsina, D. Arnold, I. Ben-Aharon, M. Collienne, MP. Lutz, C. Neuzillet, R. Obermannova, M. Peeters, F. Sclafani, E. Smyth, JW. Valle, AD. Wagner, L. Wyrwicz, E. Fontana, M. Moehler
Jazyk angličtina Země Velká Británie
Typ dokumentu kongresy, časopisecké články, přehledy, práce podpořená grantem
NLK
PubMed Central
od 2016
Europe PubMed Central
od 2016
Open Access Digital Library
od 2016-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2016
- MeSH
- gastrointestinální nádory * farmakoterapie MeSH
- imunoterapie MeSH
- lékařská onkologie * MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- kongresy MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.
Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital Cambridge UK
Caritasklinikum Saarbrucken Germany
Department of Internal Medicine Johannes Gutenberg University Mainz Germany
Department of Medical Oncology Institut Jules Bordet Université Libre de Bruxelles Brussels Belgium
Department of Medical Oncology The Christie NHS Foundation Trust Manchester UK
Department of Oncology Geneva University Hospital Geneva Switzerland
Department of Oncology Universitair Ziekenhuis Antwerpen Antwerp Belgium
Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic
Division of Cancer Sciences University of Manchester Manchester UK
Division of Oncology Rambam Health Care Campus Rappaport Faculty of Medicine Technion Haifa Israel
European Organisation for Research and Treatment of Cancer Brussels Belgium
Hospital Universitario de Navarra Medical Oncology Department Pamplona Spain
Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology Warsaw Poland
Sarah Cannon Research Institute London UK
Swiss Cancer Center Leman University of Geneva Lausanne Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018949
- 003
- CZ-PrNML
- 005
- 20220804135215.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.esmoop.2022.100392 $2 doi
- 035 __
- $a (PubMed)35180656
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Koessler, T $u Department of Oncology, Geneva University Hospital, Geneva, Switzerland; Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. Electronic address: Thibaud.kossler@hcuge.ch
- 245 10
- $a ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective / $c T. Koessler, M. Alsina, D. Arnold, I. Ben-Aharon, M. Collienne, MP. Lutz, C. Neuzillet, R. Obermannova, M. Peeters, F. Sclafani, E. Smyth, JW. Valle, AD. Wagner, L. Wyrwicz, E. Fontana, M. Moehler
- 520 9_
- $a There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.
- 650 12
- $a gastrointestinální nádory $x farmakoterapie $7 D005770
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $7 D007167
- 650 12
- $a lékařská onkologie $7 D008495
- 655 _2
- $a kongresy $7 D016423
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Alsina, M $u Hospital Universitario de Navarra (HUN), Medical Oncology Department, Pamplona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 700 1_
- $a Arnold, D $u Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany
- 700 1_
- $a Ben-Aharon, I $u Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel
- 700 1_
- $a Collienne, M $u Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany; European Organisation for Research and Treatment of Cancer, Brussels, Belgium
- 700 1_
- $a Lutz, M P $u Caritasklinikum, Saarbrucken, Germany
- 700 1_
- $a Neuzillet, C $u GI Oncology, Medical Oncology Department, Institut Curie Saint-Cloud, Versailles Saint Quentin University, Saint-Cloud, France
- 700 1_
- $a Obermannova, R $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno; Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Peeters, M $u Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
- 700 1_
- $a Sclafani, F $u Department of Medical Oncology, Institut Jules Bordet-Université Libre de Bruxelles (ULB), Brussels, Belgium
- 700 1_
- $a Smyth, E $u Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK
- 700 1_
- $a Valle, J W $u Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
- 700 1_
- $a Wagner, A D $u Department of Oncology, Division of Medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
- 700 1_
- $a Wyrwicz, L $u Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Fontana, E $u Sarah Cannon Research Institute, London, UK
- 700 1_
- $a Moehler, M $u Department of Internal Medicine, Johannes-Gutenberg University, Mainz, Germany
- 773 0_
- $w MED00196632 $t ESMO open $x 2059-7029 $g Roč. 7, č. 2 (2022), s. 100392
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35180656 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135208 $b ABA008
- 999 __
- $a ok $b bmc $g 1822508 $s 1170192
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 7 $c 2 $d 100392 $e 20220216 $i 2059-7029 $m ESMO open $n ESMO Open $x MED00196632
- LZP __
- $a Pubmed-20220720
